TY - JOUR T1 - Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. AU - Tan,D, AU - Matsumoto,A, AU - Conry-Cantilena,C, AU - Melpolder,J C, AU - Shih,J W, AU - Leuther,M, AU - Hess,G, AU - Gibble,J W, AU - Ness,P M, AU - Alter,H J, PY - 1999/4/7/pubmed PY - 2000/3/21/medline PY - 1999/4/7/entrez SP - 1055 EP - 61 JF - The Journal of infectious diseases JO - J Infect Dis VL - 179 IS - 5 N2 - Serologic, biochemical, and molecular analyses were used to study hepatitis G virus (HGV), antibody to the HGV envelope protein (anti-E2), risk factors, clinical significance, and the impact of HGV on coexistent hepatitis C virus (HCV). Among 329 donors with confirmed HCV infection, 12% were HGV RNA-positive and 44% were anti-E2-positive (total exposure, 56%). HGV RNA and anti-E2 were mutually exclusive except in 9 donors (1.5%); 8 of 9 subsequently lost HGV RNA but anti-E2 persisted. HGV had little impact on alanine aminotransferase, aspartate aminotransferase, or gamma-glutamyl transpeptidase in donors with HGV infection alone or those coinfected with HCV. A multivariate analysis showed that intravenous drug abuse was the leading risk factor for HGV transmission, followed by blood transfusion, snorting cocaine, imprisonment, and a history of sexually transmitted diseases. In summary, HGV and HCV infections were frequently associated and shared common parenteral risk factors; HGV did not appear to cause hepatitis or to worsen the course of coexistent hepatitis C. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/10191204/Analysis_of_hepatitis_G_virus__HGV__RNA_antibody_to_HGV_envelope_protein_and_risk_factors_for_blood_donors_coinfected_with_HGV_and_hepatitis_C_virus_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/314722 DB - PRIME DP - Unbound Medicine ER -